Dendreon(DNDN) Receives FDA Approval for Therapeutic Cancer Vaccine
New Treatment Category for Cancer-Autologous Cellular Immunotherapy The FDA cleared the first therapeutic vaccine for cancer with Dendreon’s Provenge (R)(Sipuleucel-T), an individualized treatment approach for advanced prostate cancer (CRPC). CRPC is asymptomatic or minimally symptomatic, metastatic,castrate-resistant (hormone refractory) prostate cancer.Provenge takes the patient’s own immune cells and infuses them back thereby priming the immune system […]
